Skip to main content
SpringerLink
Log in

The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Serum-soluble interleukin-2 receptor (IL-2R) concentrations have been found to be elevated in cancer patients. However, the importance of this finding in patients with non-small-cell lung cancer (NSCLC) has not been previously established.

Methods

Preoperative serum-soluble IL-2R concentrations were determined in 65 consecutive patients with operable NSCLC. The correlation of preoperative serum-soluble IL-2R concentrations with various clinicopathological features of this cancer was evaluated to clarify the clinical significance of this parameter.

Results

Although serum-soluble IL-2R concentrations were not significantly higher in operable NSCLC patients than in normal controls (P=.1180), serum-soluble IL-2R concentrations were significantly higher in patients with stage IIIB or IV disease than in normal controls (P=.0001). The presence of intrapulmonary metastasis was the only clinicopathological feature that was significantly correlated to serum-soluble IL-2R concentration (P=.0004). The sensitivity of serum-soluble IL-2R concentration in identifying the presence of intrapulmonary metastasis was 87.5%; specificity was 75%.

Conclusions

Elevated preoperative serum-soluble IL-2R concentrations in patients with operable NSCLC reflect the occurrence of intrapulmonary metastasis. Preoperative examination of serum-soluble IL-2R concentrations may be valuable in the detection of the intrapulmonary metastasis preoperatively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Smith KA. Interleukin-2: inception, impact, and implications.Science 1988; 240:1169–76.

    Article  PubMed  CAS  Google Scholar 

  2. Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes.Science 1986; 232:727–32.

    Article  PubMed  CAS  Google Scholar 

  3. Muller C, Knoflach P, Zielinski C. Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver diseases.Hepatology 1989; 10:928–32.

    PubMed  CAS  Google Scholar 

  4. Kloster BE, John PA, Miller LE, et al. Soluble interleukin-2 receptors are elevated in patients with AIDS or at risk of developing AIDS.Clin Immunol Immunopathol 1987; 45:440–6.

    Article  PubMed  CAS  Google Scholar 

  5. Prince HE, Kleinman S, Williams AE. Soluble IL-2R receptors in serum from blood donors seropositive for HIV.J Immunol 1988; 140:1139–41.

    PubMed  CAS  Google Scholar 

  6. Lawrence EC, Berger MB, Brousseau, KP, et al. Elevated serum levels of soluble interleukin-2 receptors in active pulmonary sarcoidosis: relative specificity and association with hypercalcemia.Sarcoidosis 1987; 4:87–93.

    PubMed  CAS  Google Scholar 

  7. Lawrence EC, Brousseau KP, Berger MK, Kurman CC, Marcon L, Nelson DL. Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage in active sarcoidosis.Am Rev Respir Dis 1988; 137:759–64.

    PubMed  CAS  Google Scholar 

  8. Brown AE, Rieder KT, Webster HK. Prolonged elevations of soluble interleukin-2 receptors in tuberculosis.Am Rev Respir Dis 1989; 139:1036–8.

    PubMed  CAS  Google Scholar 

  9. Nakanishi K, Taniguchi Y. Increased levels of soluble interleukin 2 receptors in Grave’s disease. Proceedings of the Eighth International Congress of Endocrinology, Kyoto, July 17–23, 1988:267A.

  10. Chilosi M, Pizzolo G, Semenzato G, Getto G. Detection of a soluble form of the receptor for interleukin-2 in the serum of patients with hairy cell leukaemia.Int J Biol Markers 1986; 1:101–4.

    PubMed  CAS  Google Scholar 

  11. Wagner DK, Kiwanuka J, Edwards BK, Rubin LA, Nelson DL, Magrath IT. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival.J Clin Oncol 1987; 5:1262–74.

    PubMed  CAS  Google Scholar 

  12. Pizzolo G, Chilosi M, Vinante F, et al. Soluble interleukin-2 receptors in the serum of patients with Hodgkin’s disease.Br J Cancer 1987; 55:427–8.

    PubMed  CAS  Google Scholar 

  13. Rovelli F, Lissoni P, Crispino S, et al. Increased levels of soluble interleukin-2 receptors in solid tumors: a preliminary study.Tumori 1988; 74:633–7.

    PubMed  CAS  Google Scholar 

  14. Lissoni B, Barni S, Rovelli F, et al. The biological significance of soluble interleukin-2 receptors in solid tumors.Eur J Cancer 1990; 26:33–6.

    Article  PubMed  CAS  Google Scholar 

  15. Marino P, Cugno M, Preatoni A, et al. Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer.Br J Cancer 1990; 61:435–6.

    Google Scholar 

  16. Buccheri G, Marino P, Preatoni A, Ferrigno D, Moroni GA. Soluble interleukin 2 receptor in lung cancer: an indirect marker of tumor activity.Chest 1991; 99:1433–7.

    PubMed  CAS  Google Scholar 

  17. Ginns LC, De Hoyos A., Brown MC, Gaumond BR. Elevated concentration of soluble interleukin-2 receptors in serum of smokers and patients with lung cancer: correlation with clinical activity.Am Rev Respir Dis 1990; 142:398–402.

    PubMed  CAS  Google Scholar 

  18. Tisi E, Lissoni P, Angeli M et al. Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma.Cancer 1992; 69:2458–62.

    Article  PubMed  CAS  Google Scholar 

  19. Mountain CF. A new international staging system for lung cancer.Chest 1986; 89 (Suppl):225–33.

    Google Scholar 

  20. The World Health Organization. Histological typing of lung tumors.Am J Clin Pathol 1982; 57:471–621.

    Google Scholar 

  21. Mountain CF. Revisions in the International System for Staging Lung Cancer.Chest 1997; 111:1710–7.

    PubMed  CAS  Google Scholar 

  22. Yano T, Yoshino I, Yokoyama H, et al. The clinical significance of serum soluble interleukin-2 receptors in lung cancer.Lung Cancer 1996; 15:79–84.

    Article  PubMed  CAS  Google Scholar 

  23. Murakami S, Satomi A, Ishida K, Murai H, Matsuki M, Hashimoto T. Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer.Cancer 1994; 74:2745–8.

    Article  PubMed  CAS  Google Scholar 

  24. Tamura K, Shibata Y, Matsuda Y, Ishida N. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients.Cancer Res 1981; 41:3244–52.

    PubMed  CAS  Google Scholar 

  25. Sawada M, Okudaira Y, Matsui Y, Shimizu Y. Immunosuppressive acidic protein in patients with ovarian cancer.Cancer 1983; 52:2081–5.

    Article  PubMed  CAS  Google Scholar 

  26. Miki T, Saiki S, Kinouchi T, et al. Immunosuppressive acidic protein in patients with testicular cancer.J Urol 1987; 137:48–52.

    PubMed  CAS  Google Scholar 

  27. Tamura S, Nishigaki T, Moriwaki Y, et al. Tumor markers in pleural effusion diagnosis.Cancer 1988; 61:298–302.

    Article  PubMed  CAS  Google Scholar 

  28. Seki H, Tsukamoto T, Aso H, Tamura K. Intrathecal synthesis of immunosuppressive acidic protein (IAP) in patients with multiple sclerosis and other inflammatory neurological diseases.J Neurol Sci 1988; 85:259–66.

    Article  PubMed  CAS  Google Scholar 

  29. Lee YC, Yang PC, Kou SH, Luh KT. Immunosuppressive acidic protein in patients with lung cancer.Chest 1992; 102:1491–5.

    PubMed  CAS  Google Scholar 

  30. Aozasa K, Ueda T, Ayata M, et al. Immunohistochemical determination of immunosuppressive acidic protein in reactive and neoplastic diseases of macrophage.Cancer 1987; 60:2414–7.

    Google Scholar 

  31. Yano T, Fukuyama Y, Yokoyama H, et al. Interleukin-2 receptors in pulmonary adenocarcinoma.Lung Cancer 1996; 16:13–9.

    Article  PubMed  CAS  Google Scholar 

  32. Yoshino I, Nakanishi R, Osaki T, et al. Postoperative prognosis in patients with non-small cell lung cancer with synchronous ipsilateral intrapulmonary metastasis.Ann Thorac Surg 1997; 64:809–13.

    Article  PubMed  CAS  Google Scholar 

  33. Deslauriers J, Brisson J, Cartier R, et al. Carcinoma of the lung: evaluation of satellite nodules as a factor influencing prognosis after resection.J Thorac Cardiovasc Surg 1989; 97:504–12.

    PubMed  CAS  Google Scholar 

  34. Naruke T, Yamasaki S. The results of surgical treatment of lung cancer with intrapulmonary metastasis [in Japanese]Chiryougaku 1989; 23:193–7.

    Google Scholar 

  35. Saisho T, Nishiyama H, Takahashi K. Analysis of resected stage IV lung cancer cases [in Japanese]Jpn J Lung Cancer 1988; 28:183–8.

    Google Scholar 

  36. Ichinose Y, Hara N, Ohta M. Synchronous lung cancers defined by deoxyribonucleic acid flow cytometry.J Thorac Cardiovasc Surg 1991; 102:418–24.

    PubMed  CAS  Google Scholar 

  37. Mc Elvaney G, Miller RR, Muller NL, Nelems B, Evans KG, Ostrow DN. Multicentricity of adenocarcinoma of the lung.Chest 1989; 95:151–4.

    Google Scholar 

  38. Kunitoh H, Eguchi K, Yamada K, et al. Intrapulmonary sublesions detected before surgery in patients with lung cancer.Cancer 1992; 70:1876–9.

    Article  PubMed  CAS  Google Scholar 

  39. Shimizu N, Ando A, Date H, Teramoto S. Prognosis of undetected intrapulmonary metastases in resected lung cancer.Cancer 1993; 71:3868–72.

    Article  PubMed  CAS  Google Scholar 

  40. Yoshino I, Nakanishi R, Osaki T, et al. Postoperative prognosis in patients with non-small cell lung cancer with synchronous ipsilateral intrapulmonary metastasis.Ann Thorac Surg 1997; 64:809–13.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine, National Sanatorium Nishigunma Hospital, Gunma, Japan

    Ryusei Saito MD

  2. Second Department of Surgery, Gunma University School of Medicine, Gunma, Japan

    Yasuo Morishita MD

  3. Department of Surgery, National Sanatorium Nishigunma Hospital, 2854 Kanai, 377-8511, Shibukawa, Gunma, Japan

    Osamu Kawashima MD, Mitsuhiro Kamiyoshihara MD, Shuji Sakata MD & Keiichi Endo MD

Authors
  1. Osamu Kawashima MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsuhiro Kamiyoshihara MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuji Sakata MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keiichi Endo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryusei Saito MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuo Morishita MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Osamu Kawashima MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kawashima, O., Kamiyoshihara, M., Sakata, S. et al. The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients. Annals of Surgical Oncology 7, 239–245 (2000). https://doi.org/10.1007/BF02523660

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02523660

Key Words

Search

Navigation